证券之星消息，8月12日水泥板块较上一交易日下跌1.85%，天山股份领跌。当日上证指数报收于 3665.92，上涨0.5%。深证成指报收于11351.63，上涨0.53%。水泥板块个股涨跌见下表： 从资金流向上来看，当日水泥板块主力资金净流出10.47亿元，游资资金净流出6442.66万元，散户资金净 流入11.12亿元。水泥板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 000672 上峰水泥 | | = 191.19万 | 1.81% | -621.94万 | -5.88% | 430.75万 | 4.07% | | 002671 龙泉股份 | | -108.92万 | -2.10% | 139.51万 | 2.69% | -30.59万 | -0.59% | | 605122 四方新材 | | -360.78万 | -6.26% | 111.49万 | 1.93% | 249.29万 ...

Group 1 - The first Shantou Health Industry Innovation Development Conference and Health Product Expo was successfully held from August 8 to 10, 2025, with the theme "Healthy China, Vibrant Shantou" [1] - Guangdong Wannianqing Pharmaceutical Co., Ltd. (referred to as "Yue Wannianqing") participated deeply as an important co-organizer and exhibitor, showcasing its innovative capabilities and strategic layout covering the "Traditional Chinese Medicine +" industry chain [1] - Yue Wannianqing's business scope includes pharmaceuticals, traditional Chinese medicine pieces, and health supplements, and it presented its core sectors such as Huahuaitang Traditional Chinese Medicine Hall and various health service centers [1] Group 2 - During the opening ceremony, Yue Wannianqing's Chairman Ou Xiantao and Vice President Chen Xiuyan participated in the launch and signing of several important projects, including a strategic cooperation with the Jinping District Government and Shantou University, marking a new stage in government-enterprise collaborative development [1] - Following the expo, Yue Wannianqing, in collaboration with the Shantou Listed Companies Development Promotion Association and Guangzhou Private Equity Fund Association, held a themed roadshow focusing on "Value Management and High-Quality Development," attracting numerous listed companies, excellent enterprises, investment institutions, and financial media [2] - The company, recognized as a "Chinese Time-Honored Brand" and a "Cultural Heritage," is actively responding to the national strategy for revitalizing traditional Chinese medicine and seizing historical opportunities for high-quality development in the health industry [2]

Group 1 - The core viewpoint of the news is that Guangdong Wannianqing Pharmaceutical Co., Ltd. has experienced a decline in its stock price and financial performance, indicating potential challenges for the company [1][3]. - As of August 8, 2025, the stock price of Guangdong Wannianqing is 18.23 yuan, down 3.44%, with a turnover rate of 6.16% and a trading volume of 98,500 hands, amounting to 181 million yuan [1]. - The company reported total revenue of 70.81 million yuan for the first quarter of 2025, a year-on-year decrease of 0.54%, and a net profit attributable to shareholders of 3.44 million yuan, down 129.32% year-on-year [1]. Group 2 - The company has made investments in 10 enterprises and participated in 4,604 bidding projects, indicating active engagement in business development [2]. - Guangdong Wannianqing holds 51 trademark registrations and 47 patents, showcasing its focus on intellectual property [2]. - The company has 133 administrative licenses, reflecting its compliance and operational capabilities within the pharmaceutical industry [2].

Group 1 - The stock price of Yue Wannianqing closed at 18.42 yuan on August 5, 2025, down 0.58 yuan, a decrease of 3.05% from the previous trading day [1] - The trading volume on that day was 119,714 hands, with a transaction amount of 223 million yuan [1] - The company specializes in the research, production, and sales of traditional Chinese medicine, primarily focusing on cold-related medications [1] Group 2 - In the first quarter of 2025, the company reported operating revenue of 70.81 million yuan and a net loss of 3.44 million yuan [1] - Shareholder Hehe Investment reduced its holdings by 895,000 shares on August 4, decreasing its ownership from 8.22% to 7.66% [1] - The company stated on its investor interaction platform that it currently does not produce or sell any drugs specifically targeting Chikungunya virus [1] Group 3 - On August 5, the net outflow of main funds was 14.56 million yuan, accounting for 0.49% of the circulating market value [1] - Over the past five trading days, the cumulative net inflow of main funds was 8.73 million yuan, representing 0.3% of the circulating market value [1]

Core Viewpoint - Guangdong Wannianqing Pharmaceutical Co., Ltd. announced that its major shareholder, Hehe Investment Holdings (Guangzhou) Partnership, plans to reduce its shareholding by up to 4,800,000 shares, representing a maximum of 3.00% of the company's total share capital [1][3]. Summary by Sections Shareholder Reduction Plan - Hehe Investment plans to reduce its holdings within three months starting from fifteen trading days after the announcement date [1][3]. - The reduction will be executed through centralized bidding and block trading methods [1][3]. Recent Shareholding Changes - On August 4, 2025, Hehe Investment reduced its holdings by 895,000 shares, decreasing its ownership from 8.2173125% to 7.6579375%, which is a change of 1% of the total share capital [2]. - The total shares held by Hehe Investment after the reduction are 1,225.27 million shares [2]. Compliance and Regulations - The reduction is in line with the previously disclosed reduction plan, and the actual number of shares reduced does not exceed the planned amount [3][4]. - The company confirms that the reduction does not violate any laws or regulations, and there are no restrictions on the shares being reduced [3][4].

金融界消息 截至2025年8月5日收盘，粤万年青（301111）报收于18.42元，下跌3.05%，换手率7.48%， 成交量11.97万手，成交金额2.23亿元。 来源：金融界 天眼查商业履历信息显示，广东万年青制药股份有限公司，成立于1981年，位于汕头市，是一家以从事 医药制造业为主的企业。企业注册资本16000万人民币，实缴资本11999.736万人民币。公司法定代表人 为欧先涛。 通过天眼查大数据分析，广东万年青制药股份有限公司共对外投资了10家企业，参与招投标项目4604 次，知识产权方面有商标信息51条，专利信息47条，此外企业还拥有行政许可133个。 资金流向方面，今日主力资金净流出1456.08万元，占比成交额6.52%。其中，超大单净流入108.17万 元、占成交额0.48%，大单净流出1564.25万元、占成交额7.01%，中单净流出流出611.11万元、占成交 额2.74%，小单净流入2067.19万元、占成交额9.26%。 粤万年青最新一期业绩显示，截至2025一季报，公司营业总收入7081.26万元、同比减少0.54%，归属净 利润344.17万元，同比减少129.32%，扣非净利 ...

格隆汇8月5日丨粤万年青(301111.SZ)公布，公司近日收到合和投资的《告知函》，获悉合和投资于2025 年8月4日通过集中竞价及大宗交易的方式累计减持公司股份89.50万股，减持后合和投资持股比例由 8.2173125%变更为7.6579375%，本次变动触及公司总股本的1%。 ...

格隆汇8月5日丨粤万年青(301111.SZ)在互动平台表示，公司目前未生产或销售直接针对基孔肯雅热的药 品。基孔肯雅热是由基孔肯雅病毒引起，经伊蚊叮咬传播的病毒性传染病，其典型症状为发热。公司产 品中羚羊感冒胶囊功能主治清热解表。用于流行性感冒，伤风咳嗽，头晕发热，咽喉肿痛。除此之外， 感冒类产品还有扑感片、银菊清解片及银翘解毒合剂等，具体适用场景请以产品说明书或遵医嘱为准。 公司始终重视研发创新，目前公司在研产品及项目正在积极推进中，包括中药创新药研发和现有品种的 二次开发。未来，公司将继续加大研发投入，积极与汕头大学等高校探索产学研合作新模式，促进协同 创新，推动中医药现代化发展，增强公司的核心竞争力。 （原标题：粤万年青(301111.SZ)：目前未生产或销售直接针对基孔肯雅热的药品） ...

Group 1 - The core viewpoint of the news is that Jiangxi Wannianqing Cement Co., Ltd. has shown a significant increase in net profit despite a decrease in total revenue for the first quarter of 2025 [1] - As of August 1, 2025, the stock price of Wannianqing is reported at 6.11 yuan, with a trading volume of 94,300 hands and a transaction amount of 57.36 million yuan [1] - The company experienced a net inflow of main funds amounting to 10.15 million yuan, representing 17.69% of the total transaction amount [1] Group 2 - For the first quarter of 2025, the company reported total operating revenue of 1.063 billion yuan, a year-on-year decrease of 16.63% [1] - The net profit attributable to shareholders reached 35.35 million yuan, showing a year-on-year increase of 477.58% [1] - The company has a current ratio of 2.154, a quick ratio of 2.032, and a debt-to-asset ratio of 37.59% [1] Group 3 - Jiangxi Wannianqing Cement Co., Ltd. was established in 1997 and is primarily engaged in the non-metallic mineral products industry [2] - The company has made investments in 44 enterprises and participated in 5,000 bidding projects [2] - It holds 115 trademark registrations and 20 patents, along with 60 administrative licenses [2]

8月1日，粤万年青大宗交易成交25.8万股，成交额400.16万元，占当日总成交额的1.92%，成交价15.51 元，较市场收盘价18.15元折价14.55%。 ...